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Abstract 19 
Acinetobacter baumannii has been identified by the WHO as a high priority pathogen. It 20 
can be resistant to multiple antibiotics and colistin sulphate is often used as a last-resort 21 
treatment. However, the potentially severe side-effects of colistin are well documented and 22 
this study compared the bactericidal and anti-biofilm activity of two synthetic nature-inspired 23 
antimicrobial peptides, bicarinalin and BP100, with colistin. The minimum bactericidal 24 
concentration (MBC) against planktonic A. baumannii was approximately 0.5 µg/ml for colistin 25 
sulphate and ~4 µg/ml for bicarinalin and BP100. A. baumannii commonly occurs as a biofilm 26 
and biofilm removal assay results highlighted that both bicarinalin and BP100 had significantly 27 
greater potential than colistin. Atomic force microscopy (AFM) showed dramatic changes in A. 28 
baumannii cell size and surface conformity when treated with peptide concentrations at and 29 
above the MBC. Scanning electron microscopy (SEM) visualised the reduction of biofilm 30 
coverage and cell surface changes as peptide concentration increased. Liposome assays 31 
revealed that these peptides most likely act as pore-forming agents in the membrane. 32 
Bicarinalin and BP100 may be effective therapeutic alternatives to colistin against A. baumannii 33 
infections but further research is required to assess if they elicit cytotoxicity issues in patients. 34 
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Introduction 38 
It has been widely publicised that by 2050, deaths due to antimicrobial resistant (AMR) 39 
infections may rise to 10 million per year and during that time, 300 million people will die from 40 
AMR infections [1]. The abuse of currently used antimicrobials, the paucity of new 41 
antimicrobials progressing successfully through clinical trials and the evolution of bacterial 42 
resistance mechanisms have led to the prospect of returning to the pre-antibiotic era when 43 
patients were dying from infections through minor injuries and routine surgeries. Although the 44 
recent development of novel antibiotics [2, 3] has provided reason for optimism, these drugs 45 
are generally limited to the treatment of Gram-positive infections while Gram-negative 46 
pathogens remain of significant concern [4].  47 
Acinetobacter baumannii is one such opportunistic pathogen [5, 6] occurring almost 48 
exclusively in the hospital environment and is particularly prevalent in intensive care and burns 49 
units; it has been reported to be responsible for between 2-10% of all Gram-negative 50 
nosocomial infections [7]. A member of the ‘ESKAPE’ group [8] of pathogens, A. baumannii is 51 
able to persist on clinical surfaces by forming biofilms [7, 9], an ability that renders bacteria 52 
more resistant to many common antimicrobials [10, 11] leading to  A. baumannii infections 53 
becoming rapidly more difficult to treat [12]. It is able to persist for long periods on fomites [7, 54 
9] enabling the pathogen to cause widespread epidemic infections in nosocomial settings. 55 
Current treatments include β-lactam antibiotics with the carbapenems typically the treatment 56 
of choice [9].  57 
Antimicrobial peptides (AMPs) have been much heralded as alternatives to antibiotics 58 
due to their ability to destroy multi-drug resistant (MDR) bacteria [13]. One example is colistin 59 
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sulphate (colistin), commonly used as a last resort treatment for MDR A. baumannii infections 60 
[14]. However, the toxicity of colistin in patients is well known [13, 14] and resistance is 61 
increasingly described [15-17] resulting in a crucial search for improved alternatives.  62 
The aim of this study was to establish and visualise the activity of two little researched 63 
AMPs, bicarinalin and BP100, which may be appropriate for use instead of colistin to treat MDR 64 
A. baumannii infections. Bicarinalin is an amphipathic, C-terminally amidated, novel 65 
antimicrobial peptide derived from the venom of the myrmicine ant, Tetramorium bicarinatum 66 
[18, 19]. It consists of a sequence of 20 amino acid residues (KIKIPWGKVKDFLVGGMKAV) with a 67 
molecular weight of 2213.78 g/mol. The action of bicarinalin has been evaluated against a 68 
selection of Gram-positive and Gram-negative organisms [18, 19] and has been found to have 69 
good antibacterial activity compared to other AMPs together with less haemolytic activity. 70 
BP100 is a short C-amidated undecapeptide consisting of 11 amino acids (KKLFKKILKYL) 71 
and a molecular weight of 1420.88 g/mol. It was originally synthesised by combinatorial 72 
chemistry involving two peptides, cecropin A and melittin [20]. Cecropin A is a member of the 73 
well-researched AMP family, the cecropins, first isolated from the giant silk moth Hyalophora 74 
cecropia. The cecropin family, although susceptible to protease degradation, does not exhibit 75 
cytotoxic effects against human erythrocytes [21, 22]. Melittin is a 26 amino acid, haemolytic 76 
alpha helical peptide first purified from the European honeybee in 1958 [23], with 77 
demonstrated antibacterial activity [24]. However, on its own, melittin’s strong cytotoxic action 78 
makes it unsuitable for clinical applications [25]. To circumvent cecropin A’s susceptibility to 79 
proteolytic degradation and melittin’s high cytotoxicity, they were combined to produce a 80 
derivative, BP100. BP100 exhibits low susceptibility to protease degradation and lower 81 
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cytotoxicity against erythrocytes and fibroblasts [26]. BP100 has been established to have good 82 
antibacterial activity against several Gram-negative bacteria [20, 22].  83 
It is believed that bicarinalin’s antibacterial mechanism is similar to other AMPs, with its 84 
cationic charge, as a result of lysine residues, naturally attracted to the anionic charged 85 
bacterial cell surface. It is also believed that BP100 interacts with the bacterial cell membrane 86 
via electrostatic attraction to the negatively charged LPS layer, causing blebbing on the surface 87 
leading to a collapse of the outer membrane [20].  88 
The aim of this study was to assess the potential of bicarinalin and BP100 as alternatives 89 
to colistin to treat A. baumannii infections. The study also aimed to visualise the effects of these 90 
antimicrobial agents on A. baumannii cells and biofilms using scanning electron microscopy 91 
(SEM) and atomic force microscopy (AFM).  92 
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Materials and methods 93 
Bacterial culture conditions 94 
Fresh cultures of Acinetobacter baumannii (ATCC® 19606) were prepared by streaking a 95 
culti-loop (ThermoFisher Scientific, UK) on freshly prepared Tryptone Soya Agar (TSA, Oxoid, 96 
UK) and incubated for 24 h at 37 °C. Purity was assessed using Gram staining, cell morphology, 97 
oxidase and Analytical Profile Index (API, Biomérieux, UK, 20NE kit) testing. A standard growth 98 
curve for the A. baumannii was established to ensure mid-log phase growth and an initial 99 
inoculum of 5x10
5
 CFU/ml at the start of each experiment. 100 
Antimicrobial assays 101 
Minimum inhibitory concentration (MIC) 102 
The MIC was determined for each of the antimicrobial agents studied: colistin (Sigma-103 
Aldrich, UK), bicarinalin (97.7% purity, Genscript, USA) and BP100 (98.4% purity, Genscript, 104 
USA). 10 ml of sterile Tryptone Soya Broth (TSB, Oxoid, UK) was inoculated with 2-3 colonies of 105 
A. baumannii and incubated overnight at 37 °C and later diluted to an absorbance that equated 106 
to 1x10
6
 CFU/ml. 107 
Antimicrobial solutions were prepared and sterilised by filtering through a 0.2 µm 108 
minisart single use sterile filter (Sartorius-Stedim Biotech, Fisherscientific, UK). Stock solutions 109 
(1024 µg/ml) were prepared, taking into account the stated product purity. Reduction of 110 
peptide concentration through filtration was not assayed for. 111 
50 µl of each agent, at a stock concentration of 1024 μg/ml, was added to well 1 of a 96-112 
well microplate (Fisherscientific, UK) and a two-fold dilution series prepared in wells 2 to 12. 50 113 
µl of inoculated TSB, containing 1x10
6
 CFU/ml of A. baumannii, was then added to each well 114 
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resulting in final peptide concentrations from 256 μg/ml to 0.125 μg/ml and a cell density of 115 
5x10
5
 CFU/ml.  Plates were covered and incubated in a shaking incubator at 37 °C and 140 rpm 116 
for 24 h. The lowest concentration of peptide where the well was visibly clear was recorded as 117 
the MIC. The entire experiment was carried out three times in triplicate to give nine datasets 118 
and the mean MIC established.  119 
Minimum bactericidal concentration (MBC) 120 
After recording the MIC, spread plates were prepared on TSA using 100 µl from each 121 
clear well. These plates were incubated at 37 °C for 24 h. The lowest concentration where there 122 
was no growth observed on the plate was recorded as the MBC. This was carried out after each 123 
MIC test and therefore three times in triplicate. 124 
Minimum biofilm inhibitory concentration (MBIC) 125 
A 96-well microplate plate containing doubling dilutions of antimicrobial was incubated 126 
with 5x10
5
 CFU/ml A. baumannii for 24 h at 37 °C, 140 rpm. After 24 h, the wells were emptied 127 
and washed three times with ¼ strength Ringer’s solution and air dried for 1 h. 1% crystal violet 128 
solution was added to each well and left at room temperature for 10 minutes. The wells were 129 
emptied by pipetting, washed three times with distilled water, and air dried for 30 minutes at 130 
37 °C. The stain was solubilised with 96% ethanol (100 µl). The plate was covered and shaken at 131 
140 rpm for 30 minutes. 2 µl was removed and the absorbance of the solution was measured at 132 
590 nm compared to a 96% ethanol blank. This was replicated three times and the mean 133 
calculated. The percentage biofilm inhibited was calculated by comparing against an untreated 134 
bacterial control. SPSS Statistics 21 (IBM, USA) was used for the statistical analysis of MBIC 135 
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results. The samples t-test was used to find if there was a statistical difference of 95% (p≤0.05, 136 
statistically significant) or 99% (p≤0.01, highly significant). 137 
Biofilm removal assay 138 
Biofilms of A. baumannii were grown in 36 wells of a 96-well microplate (test plate) by 139 
adding 50 µl sterile TSB and 50 µl of TSB inoculated with 1x10
6
 CFU/ml culture. Plates were 140 
incubated at 37 °C, 140 rpm for 24 h. On a separate 96-well microplate (titration plate) a 141 
doubling dilution series was prepared with 75 µl of TSB and 75 µl of antimicrobial solution 142 
(stock concentration, 8192 µg/ml). The wells containing biofilm were washed three times with 143 
¼ strength Ringer’s solution and 75 µl sterile TSB was then added to each well. 75 µl from the 144 
titration plate, containing a specific concentration of peptide, was added to the corresponding 145 
well on the test plate. This resulted in each well containing 150 µl of TSB, which ensured the 146 
biofilm was completely submerged, and the test wells containing a doubling dilution series of 147 
antimicrobial (2048 µg/ml to 2 µg/ml). 150 µl sterile TSB was added to the negative control 148 
wells. Plates were covered and incubated in a shaking incubator for 24 h at 37 °C, 140 rpm. 149 
After incubation, the wells were emptied by tipping onto absorbent paper, washed three times 150 
with 200 µl ¼ strength Ringer’s solution and air fixed for 1 h under aseptic conditions.  151 
The percentage of biofilm removal was quantified by measuring the absorbance after 152 
applying crystal violet stain as described previously. The absorbance (at 590 nm) was 153 
determined for each sample. Biofilm reduction (%) was determined by comparison of the 154 
absorbance readings of the samples with the untreated control biofilms.  155 
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SPSS Statistics 21 software (IBM, USA) was used to assess the significance of the biofilm 156 
removal assay results. The samples t-test was applied to assess the statistical difference of 95% 157 
(p≤0.05) which was considered as statistically significant or 99% (p≤0.01) which was considered 158 
highly significant. 159 
Scanning electron microscopy 160 
A. baumannii biofilms were prepared in 150 µl TSB in 96-well microplates. Calgary 161 
Biofilm Device (CBD) lids (Nunc-TSP Screening Plate Lids, ThermoScientific, UK) were placed on 162 
the plates with the polystyrene pegs protruding into the broth. Plates were sealed and 163 
incubated at 37 °C, 140 rpm for 24 h. After incubation, the pegs were washed by submerging in 164 
200 µl of sterile ¼ strength Ringer’s solution and leaving for 2 minutes and this process was 165 
repeated twice more. Each well was then filled with 100 µl sterile TSB. 166 
Antimicrobial challenge plates were prepared, containing agent concentrations of 1 167 
µg/ml, 10 µg/ml and 100 µg/ml. The CBD lid was placed onto this challenge plate, covered and 168 
incubated at 37 °C, 140 rpm for 24 h. After 24 h the pegs were washed by submerging the CBD 169 
lid in 250 µl of sterile ¼ strength Ringer’s solution and leaving for 2 minutes and subsequently 170 
repeated twice more. 171 
0.1M sodium cacodylate buffer was prepared to give a pH reading of 7.2. The CBD pegs 172 
were then submerged in this solution for 3 minutes. 173 
2.5% glutaraldehyde solution was prepared. The CBD lid was immersed in the buffer, 174 
covered and left at ambient temperature (21 ± 2 °C) for 40 minutes. The CBD lid was then 175 
removed and twice washed in distilled water for 2 minutes. Biofilms were then dehydrated 176 
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sequentially by placing twice into 50% methanol (Fisher Scientific, UK), 70% methanol and 177 
finally 100% methanol. CBD lids were left in each solution for 2 minutes. Pegs were 178 
subsequently air dried for 4 days. 179 
Pegs were removed from the CBD lid and mounted onto 0.5” aluminium specimen 180 
stubs, fixed using carbon adhesive discs (Agar Scientific, UK). After mounting, the carbon tabs 181 
were painted with graphite and the pegs were coated with approximately 15-20 nm of 182 
platinum. A. baumannii biofilms on the surface of the pegs were visualised using a FEI Quanta 183 
FEG 650 Scanning Electron Microscope.  184 
Atomic force microscopy 185 
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Atomic force microscopy (AFM) was used to obtain topographic images of A. 186 
baumannii cells when subjected to peptide concentrations equating to ½ MBC, MBC and 2x 187 
MBC. These concentrations were 0.25, 0.5 and 1 µg/ml for colistin and 2, 4 and 8 µg/ml for both 188 
bicarinalin and BP100. 150 µl suspensions, containing inoculated TSB with A. baumannii cell 189 
density of 5x10
5
 CFU/ml and appropriate concentrations of antimicrobial, were prepared in 96-190 
well microplates. Plates were incubated at 37 °C, 140 rpm for 2 h.  191 
After incubation the suspension was pipetted onto a poly-L-lysine coated slide (Sigma 192 
Aldrich, UK) and left at ambient room temperature (21 ± 2 °C) for 20 minutes. Slides were 193 
rinsed with distilled water and left to air dry.  194 
Images were captured using a Bioscope Catalyst AFM (Bruker, Germany) operated in 195 
PeakForce tapping mode using ScanAsyst-air tips (Bruker, Germany). Images were acquired on 196 
an area of 4 µm
2
 at a scan rate of 0.5 Hz.  197 
  198 
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Vesicle leakage assays 199 
Liposomes were made from lipids extracted from A. baumannii. A. baumannii cultured 200 
at 37 °C was harvested and a total lipid extraction conducted as described by Bligh & Dyer [27], 201 
with an extra step to extract any lipid remaining in the supernatant plus 3x washing steps with 202 
1M KCl. The extracted lipid was stored in chloroform at -20 °C. A Stewart lipid assay was 203 
conducted to quantify the lipid extracted.  204 
2 mg lipid, dried from chloroform in a round-bottomed flask, was hydrated in 1 ml 100 205 
mM 5(6)-carboxyfluorescein (Sigma Aldrich, UK) and allowed to hydrate for 25 minutes with 206 
occasional shaking. The resulting suspension was extruded through a 400 nm filter and then a 207 
100 nm Nuclepore track-etched polycarbonate membrane (Whatman, UK) using a mini-208 
extruder (Avanti Polar Lipids, USA) at 37 °C. The extruded liposomes were then washed 3 times 209 
to remove un-encapsulated carboxyfluorescein by pelleting at 100,000 g and re-suspending in 210 
50 mM Tris-HCl buffer and 10 mM NaCl at pH 7.3 before final re-suspension in 1 ml of the same 211 
buffer.  212 
6.25 µl of the above liposome suspension was added to 500 µl aliquots of antimicrobial 213 
peptide solutions at the following concentrations: 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 & 512 214 
µg/ml in the above Tris buffer. An additional concentration of 0.125 µg/ml was used for colistin 215 
due to its lower MIC. 100 µl aliquots were transferred to black 96-well microplates for 216 
fluorescence measurements at 490 nm excitation and 520 nm emission using an Infinite 200Pro 217 
(Tecan, Switzerland). Carboxyfluorescein leakage was measured relative to the same quantity of 218 
liposomes suspended in 1% SDS following approximately 30 minutes exposure to the agent.  219 
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Results 220 
Antimicrobial assays 221 
MIC and MBC values were determined to be 0.5 µg/ml (0.43 µmol/L) for colistin, 4 222 
µg/ml (1.8 µmol/L) for bicarinalin and 4 µg/ml (2.8 µmol/L) for BP100 (data not shown). Fig. 1 223 
shows that the MBIC was found to be similar to the MIC and MBC for each agent with 90% of 224 
biofilm formation inhibited at 0.5 µg/ml colistin and 4 µg/ml bicarinalin and BP100. This also 225 
showed that at concentrations below the peptides’ respective MBCs, biofilm formation was 226 
possible with only 36% biofilm inhibition for colistin, 23% for bicarinalin and 20% for BP100. Fig. 227 
2 shows the eradication of a 24-hour biofilm when subjected to increasing concentrations of 228 
peptide. At 1 µg/ml of colistin, 27% of biofilm was removed. As the peptide concentration 229 
increased, more biofilm was eradicated with 52% removed at 512 µg/ml. Bicarinalin removed 230 
18% at 1 µg/ml which then increased to 70% at 128 µg/ml; no further biofilm eradication was 231 
observed with higher concentrations. BP100 removed 17% at 1 µg/ml which remained low until 232 
16 µg/ml. Above this concentration, the biofilm removed increased from 27% at 32 µg/ml to 233 
76% at 512 µg/ml, higher than both colistin and bicarinalin, to 93% at 2048 µg/ml. 234 
Microscopy 235 
SEM (Fig. 3) and AFM (Fig. 4) provide visualisation of the effects of these agents on A. 236 
baumannii cells. Fig. 3 demonstrates that, as the concentration of the agents increases, the 237 
morphological changes to the cells become more pronounced including evidence of blebbing 238 
and a more variable cell shape with shrinkage and membrane disruption. The coverage across 239 
the surface also reduces: with no addition of antimicrobial agent the cells are packed closely 240 
together and cover the whole interface; as the peptide concentration increases visible gaps are 241 
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seen between clusters of cells. The cellular morphological changes are also observed in Fig. 4 by 242 
AFM. Blebbing is observed, causing varied cell shape and shrinkage at the MBC concentrations, 243 
and the cells differ greatly compared to the cocci-bacilli shaped cells seen with no antimicrobial 244 
treatment and below the MBC.  245 
Vesicle leakage assays 246 
To determine the mechanism of action of the antimicrobial agents, a vesicle leakage 247 
assay was performed. Liposomes produced from lipids extracted from A. baumannii (Fig. 5) all 248 
leaked carboxyfluorescein in the presence of the antimicrobials. The concentration of agent 249 
causing half-maximal leakage for each agent was ~ 1.75 µg/ml for colistin, ~ 2.75 µg/ml for 250 
BP100 and ~ 2 µg/ml for bicarinalin (given maximal leakage of 70%, 65% and 56% respectively). 251 
Vesicle leakage results support the proposal that these agents exert effects on the bacterial cell 252 
membrane causing significant disruption to the cell surface (as shown in Fig. 4) and eventually 253 
cell lysis (as shown in Fig. 3).  254 
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Discussion 255 
A. baumannii susceptibility to colistin was similar to that determined by Li et al. [28] and Sauger 256 
[29], confirming that A. baumannii 19606 strain is colistin susceptible as defined by The Clinical 257 
and Laboratory Standards Institute. Bicarinalin results were compared with those of Rifflet [18]  258 
and Téné [19] who investigated Cronobacter spp., Enterobacter spp. and Staphylococcus spp.. 259 
Results suggest that A. baumannii is generally more susceptible to bicarinalin than these other 260 
bacteria. Antimicrobial activity results for BP100 against A. baumannii 19606 were comparable 261 
to other bacteria in previous studies [20, 21]. 262 
Although the MBC for both bicarinalin and BP100 was 4 µg/ml, the molar concentration of 263 
peptide differed (1.8 µmol/L for bicarinalin and 2.8 µmol/L for BP100). This is primarily due to 264 
the differences in molecular weight (bicarinalin 2213.78 g/mol, BP100 1420.88 g/mol) indicating 265 
that, although BP100 is smaller in length, it exerts a similar inhibitory and potent effect on A. 266 
baumannii. By comparison, colistin has a MBC of 0.43 µmol/L (with the smallest molecular 267 
weight, 1155.4 g/mol).   268 
MBIC results demonstrated that, at the MBC for all three antimicrobials studied, there was less 269 
than 10% biofilm formed compared to the control. Additionally, at concentrations of 270 
antimicrobial agents equal to ½ MBC (2 µg/ml for bicarinalin and BP100, 0.25 µg/ml for colistin) 271 
there was less inhibition of biofilm formation with 77% of biofilm formed in the presence of 272 
bicarinalin, 95% in BP100 and 64% in colistin.  This highlights that even below their respective 273 
MBCs, bicarinalin and colistin have some potential to prevent biofilm formation but BP100 had 274 
very little, possibly due to differences in size and mechanism of action.  275 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
 
 
 276 
Biofilm eradication results indicated that bicarinalin is superior at eradicating A. baumannii 277 
biofilms than colistin above its MBC and both bicarinalin and BP100 are more effective at 278 
concentrations above 128 µg/ml. Colistin was more effective at removing A. baumannii biofilms 279 
at low concentrations; this was as expected due to its lower MBC which is nearly an order of 280 
magnitude less than bicarinalin and BP100. However, the maximum biofilm removed was only 281 
~50% at 512 µg/ml. Bicarinalin was the most effective between 8 µg/ml, where it removed 282 
~40% of the biofilm, and 128 µg/ml, where it eradicated 70% of the biofilm. Any further 283 
increase of concentration had no additional significant effect on the biofilm. The removal 284 
activity of BP100 started slowly and at 16 µg/ml it had removed only 20% of the biofilm, half 285 
that of colistin. Above 16 µg/ml, BP100 increased relatively linearly to exceed bicarinalin activity 286 
above 512 µg/ml. At 2048 µg/ml, the highest concentration tested, BP100 had eradicated ~95% 287 
of the biofilm. Colistin had the most biofilm removal activity, as expected, at low concentrations 288 
of 1-4 µg/ml, below the MBC of bicarinalin and BP100. Bicarinalin was the most active between 289 
8 and 128 µg/ml and BP100 was the most effective from 256 to 2048 µg/ml. The superior 290 
performance of bicarinalin, and particularly that of BP100 on biofilms at higher concentrations, 291 
was not anticipated especially considering the MBC is significantly higher than colistin. 292 
The SEM has been widely used to image bacterial biofilms [30, 31], revealing, with increasing 293 
concentrations of peptide, progressive changes in cellular shape and structure of the biofilm. 294 
Membrane protrusions between bacterial cells were seen in the control sample and at 1 µg/ml 295 
concentrations for each agent in this study. Pili or cellular filaments between cells have been 296 
previously documented between cells within biofilms [32, 33]. At the higher concentrations of 297 
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10 µg/ml and 100 µg/ml, these protrusions were not visible suggesting the inability of the cells 298 
to form pili at these concentrations [34]. Fig. 3 clearly shows that as the concentration of agent 299 
is increased, the cell shape becomes less regular and the surface coverage is decreased. 300 
The effect of the antimicrobials on A. baumannii was visualised by AFM. Fig. 4 highlights that, 301 
below the peptide MBC, the coccus-bacillus cell shape is conserved. However, at concentrations 302 
at and above the MBC, the cell surface, conformation and size are drastically affected. At the 303 
highest concentrations tested there is evidence of severe disruption to the cell surface, 304 
cytoplasmic leakage and lysed cells. 305 
Membrane disruption caused by peptide activity is noted from various studies [20, 35-37]. In 306 
this study, indentations and pores are seen in the bacterial surface with resulting cytoplasmic 307 
leakage and debris, suggesting loss of turgor pressure [38]. As the peptide concentration 308 
increased, more intense membrane perturbation and cytoplasmic leakage were visualised. 309 
Similar observations were described by Li et al. [35]. 310 
Although AFM imaging of bacterial cells in air is a widely used technique [20, 39], it can lead to 311 
dehydration of the cell and changes in the cell surface that were not directly caused by peptide 312 
activity. However, all images have been compared to the control of untreated cells.  313 
The dye leakage assay reflects the relative potency of these peptides against A. baumannii, 314 
suggesting that the peptides mediate their effects through the formation of pores in the 315 
membrane although it likely reflects planktonic growth more accurately than biofilm-like 316 
structures. It cannot be directly concluded whether the peptides exert their effects on the 317 
cytoplasmic or outer membrane of the cell. The visualised bacterial cell morphological changes 318 
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seen in SEM (Fig. 3) and AFM (Fig. 4) images are likely to relate to outer membrane disorder 319 
while the vesicle leakage assay may represent disruption to the cytoplasmic membrane.  320 
Overall the results support the proposal that bicarinalin and BP100 could be used to control 321 
infections caused by biofilm-producing prokaryotes. However, Torcato et al. [40] observed 50% 322 
cytotoxicity against HELA cells at 49.2±1.4 µmol/L for BP100 which is higher than the MBC 323 
observed here (2.8 µmol/L) but lower than the concentrations needed for antibiofilm activity, 324 
suggesting that clinical antibiofilm activity of BP100 may be unlikely. Colistin performs well 325 
against planktonic cells of A. baumannii but significantly less well against biofilms. As A. 326 
baumannii is able to form biofilms, it is essential that investigations into the efficacy of novel 327 
agents are performed rigorously on biofilms.  328 
The results indicate that bicarinalin and BP100 both have similar bactericidal and generally 329 
better anti-biofilm activity against A. baumannii than colistin, with evidence supporting the idea 330 
that these peptides mediate their effects through the formation of pores in the membrane. This 331 
is encouraging but cytotoxic studies will determine whether, at these concentrations, 332 
bicarinalin and BP100 can be used in clinical treatment. 333 
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Figure legends 439 
Fig. 1: MBIC for colistin sulphate, bicarinalin and BP100. A. baumannii was subjected to a 440 
doubling dilution series (2-2048 µg/ml) of antimicrobial for 24 h. After washing and air fixing for 441 
1 h, samples were stained with 1% crystal violet. After 10 minutes the stain was solubilised with 442 
96% ethanol and the absorbance at 590 nm was read against a 96% ethanol blank. The 443 
percentage biofilm inhibited was calculated by comparing against an untreated bacterial 444 
control. The experiment was carried out three times in triplicate. 445 
Fig. 2: Percentage biofilm eradication by colistin sulphate, bicarinalin and BP100. A. 446 
baumannii biofilms were grown for 24 h and then subjected to a doubling dilution series (2-447 
2048µg/ml) of antimicrobial for 24 h. After washing and air fixing for 1 h, samples were stained 448 
with 1% crystal violet. After 10 minutes the stain was solubilised with 96% ethanol and the 449 
absorbance at 590 nm was read against a 96% ethanol blank. The percentage biofilm eradicated 450 
was calculated by comparing against an untreated bacterial control. The experiment was 451 
carried out twice in triplicate. 452 
Fig. 3: SEM Images of A. baumannii biofilms. Biofilms were grown for 24 h then treated 453 
for a further 24 h with colistin (A), bicarinalin (B) and BP100 (C). Control images, no 454 
antimicrobial (1), 1 µg/ml (2), 10 µg/ml (3), 100 µg/ml (4). Scale bars on main images are 1 µm, 455 
10 µm on inset images. 456 
Fig. 4: AFM Images of A. baumannii cells after being treated with colistin (A), bicarinalin 457 
(B) and BP100 (C) for 2 h and fixed onto a glass slide coated with poly-L-lysine. Control images, 458 
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no antimicrobial (1), 1/2 MBC (2), MBC (3), 2X MBC (4). Images were 4 µm
2
 and 256 lines at 0.5 459 
Hz. Scale bars are 1 µm. 460 
Fig. 5: The relative leakage of carboxyfluorescein from liposomes made from A. 461 
baumannii total lipid extract in the presence of increasing concentrations of the three 462 
antimicrobial agents. Error bars show the standard error around the mean of 3 replicates. 463 
N.B. As instructed, panels of Figs. 3 & 4 have been provided on a single page. They can 464 
be provided in separate files if required at a later stage.  465 
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